Top health care investment bankers say that large deals involving pharmaceutical and biotech companies are stalling as executives grapple with volatile White House economic policies that have roiled markets and set off a global trade war, Reuters’ Sabrina Valle reports. The excitement late last year over U.S. President Trump’s election and prospects for a subsequent flurry of mergers and acquisition deals has quickly faded, and political uncertainty is pushing some deals out by a few months or even quarters, according to the report. Publicly traded companies in the space include AstraZeneca (AZN), Bristol Myers (BMY), Eli Lilly (LLY), GSK (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- Needham medtech & diagnostics analyst holds analyst/industry conference call
- Pharma Giant Johnson & Johnson (JNJ) Boosts U.S. Investments by 25%
- J&J (JNJ) Commits $55B to U.S. Manufacturing Expansion as Trump’s Tariffs Pressure Mounts
- Johnson & Johnson raises U.S. investment to over $55B in next four years
- FDA approves Johnson & Johnson’s TREMFYA in Crohn’s disease